Everence Capital Management Inc. Purchases Shares of 9,800 Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Everence Capital Management Inc. purchased a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 9,800 shares of the specialty pharmaceutical company’s stock, valued at approximately $302,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Cornercap Investment Counsel Inc. raised its stake in Collegium Pharmaceutical by 4.6% in the fourth quarter. Cornercap Investment Counsel Inc. now owns 22,002 shares of the specialty pharmaceutical company’s stock valued at $677,000 after buying an additional 959 shares in the last quarter. Louisiana State Employees Retirement System acquired a new stake in Collegium Pharmaceutical in the fourth quarter valued at $502,000. Allspring Global Investments Holdings LLC raised its stake in Collegium Pharmaceutical by 10.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 45,862 shares of the specialty pharmaceutical company’s stock valued at $1,412,000 after buying an additional 4,192 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Collegium Pharmaceutical by 5.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,713 shares of the specialty pharmaceutical company’s stock valued at $514,000 after buying an additional 868 shares in the last quarter. Finally, New York State Teachers Retirement System raised its stake in Collegium Pharmaceutical by 23.2% in the fourth quarter. New York State Teachers Retirement System now owns 12,474 shares of the specialty pharmaceutical company’s stock valued at $384,000 after buying an additional 2,350 shares in the last quarter.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $34.77 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.17 and a debt-to-equity ratio of 2.48. Collegium Pharmaceutical, Inc. has a 52-week low of $20.83 and a 52-week high of $40.95. The business’s 50-day moving average price is $36.82 and its 200 day moving average price is $30.72. The firm has a market cap of $1.14 billion, a P/E ratio of 29.47 and a beta of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. The firm had revenue of $149.75 million for the quarter, compared to analyst estimates of $147.66 million. On average, equities research analysts expect that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Needham & Company LLC reiterated a “buy” rating and set a $40.00 target price on shares of Collegium Pharmaceutical in a research report on Thursday, April 11th. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 29th. Piper Sandler reiterated an “overweight” rating and set a $39.00 target price (up previously from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. Truist Financial lifted their target price on Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, February 26th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $37.00 target price (up previously from $30.00) on shares of Collegium Pharmaceutical in a research report on Thursday, January 4th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.